Abstract
Background Metabolic syndrome (MS) is a global health concern, especially for low and middle-income countries with limited resources and information. The study’s objective was to assess the prevalence of MS in Freetown, Sierra Leone, using the Adult Treatment Panel III (ATP III), International Diabetes Federation (IDF) and Harmonize ATP III. Additionally, we aimed to establish the concordance between these three different criteria used.
Methods This community-based health screening survey was conducted from October 2019 to October 2022. A multistage stratified random design was used to select adults aged 20 years and above. Mean, interquartile range (IQR), and logistic regression were used for statistical analysis. The kappa coefficient statistics resolved the agreement between these defined criteria.
Results The prevalence for NCEP ATP III, Harmonize ATP III and IDF criteria was 11.8% (95% CI: 9.0 - 15.15), 14.3% (95% CI: 11.3 - 18.0), and 8.5% (95% CI: 6.2 - 11.2), respectively for the 2,394 selected adults. The kappa coefficient (κ) agreement between the MS is: Harmonized ATP III and IDF criteria = [(208 (60.8%); (κ =0.62)]; Harmonized ATP III and NCEP ATP III = [(201 (58.7%); (κ =0.71)]; while IDF and NCEP ATP III was [(132 (38.6%); (κ =0.52)]. In the multivariable regression analysis, waist circumference correlated with all three MS criteria: ATP III [AOR = 0.85; C.I 95%: (0.40-1.78), p = 0.032], Harmonized ATP III [AOR = 1.14; C.I 95%: (0.62-2.11), p = 0.024], IDF [AOR = 1.06; C.I 95% (0.52-2.16), p = 0.018]
Conclusion We reported a high prevalence of MS in Freetown, Sierra Leone and identified waist circumference as a major risk factor for MS. This underscores the crucial role of health education and effective management of MS in Sierra Leone.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ecobank Sierra Leone Limited
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sierra Leone Ethics and Scientific Review Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
